ResMed currently trades at $218.94 per share and has shown little upside over the past six months, posting a small loss of ...

A deep-dive comparison of ResMed and Fisher & Paykel Healthcare shares: dividends, valuation, recent momentum, and which I ...

Stryker's sales have grown about 10% a year on average over the past three years, and so have ResMed's. That shared growth rate in medical devices is the bet the two have in common. Stryker (SYK) is ...

An announcement from Resmed ( ) is now available. On August 31, 2026, ResMed Inc. entered into an accelerated share repurchase agreement with Citibank to buy back $450 million of ...

Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock ...

The latest announcement is out from Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh ( (AU:RMD) ).

ResMed (RMD) stock gains as RBC Capital Markets upgrades the company to Outperform and hikes target to $262, citing positives in its Q4 FY26 results. Read more here.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

ResMed reported $1.28 billion in revenue and $2.43 EPS, driven by strong demand for AirSense 11 and effective cost management. Rising awareness of sleep apnea, aided by wearable devices like Apple ...

SAN DIEGO, Calif., Feb. 22, 2016 /PRNewswire/ -- ResMed (NYSE:RMD), the world's leading tech-driven medical device company and innovator in sleep-disordered breathing and respiratory care, today ...

ResMed stock closed at its last completed Nasdaq session on September 24, 2026, with the Nasdaq Composite ending at 26,939.37 ...